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S UMM A R Y
ALTHOUGH CURABLE, TB frequently leaves the
individual with chronic physical and psycho-social
impairment, but these consequences have been largely
neglected. The 1st International Post-Tuberculosis Sym-
posium (Stellenbosch, South Africa) was held to discuss
priorities and gaps in addressing this issue. A barrier to
progress has been the varied terminology and nomencla-
ture, so the Delphi process was used to achieve consensus
on definitions. Lack of sufficient evidence hampered
definitive recommendations in most domains, including
prevention and treatment of post-TB lung disease
(PTLD), but the discussions clarified the research needed.
A consensus was reached on a toolkit for future PTLD
measurement and on PTLD patterns to be considered.
The importance of extra-pulmonary consequences and
progressive impairment throughout the life-course was
identified, including TB recurrence and increased mor-
tality. Patient advocates emphasised the need to address
the psychological and social impacts post TB and called
for clinical guidance. More generally, there is an urgent
need for increased awareness and research into post-TB
complications.
K E Y WORD S : post-tuberculosis; impairment; sequelae;
lung health; lung disease
TUBERCULOSIS (TB) IS THE LEADING cause of
death worldwide from an infectious disease, with an
estimated 10 million cases and 1.5 million deaths in
2018.1 On the positive side, the World Health
Organization estimates that more than 58 million
people have survived TB in this century alone.1
However, unlike many other respiratory infections,
TB has the propensity to leave host tissues permanent-
ly damaged or destroyed. It thereby transitions from
being a treatable communicable disease, into a chronic
morbidity in both adults and children. The fate of TB
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survivors is uncertain, and the long-term outcomes and
drivers of morbidity and mortality after TB cure have
historically been neglected areas of research.
Post-TB morbidities include both physical impair-
ments, such as chronic lung and other organ
impairments, and psychosocial morbidities, including
ongoing stigma, anxiety/depression, social isolation
and persistent socioeconomic impairment.2 The true
burden of each of these remains poorly described,
although a growing literature describes shortened
survival post-TB. Mortality rates for TB survivors
may be as high as three times controls,3 while
prevalence estimates for lung impairment after
pulmonary TB vary from 18–87% depending on the
population studied.4
Even if these disease burden estimates are inflated,
given the 10 million annual new cases of TB each
year,1 post-TB morbidity is likely to be one of the
most important causes of chronic lung disease
globally. However, its impact is presently hidden in
the low and middle-income countries where clinical
services, research and advocacy remain inadequate.
Additionally, people completing TB treatment remain
at increased risk of developing TB again.5,6 Impor-
tantly, TB affects not just the individual, but also their
households and communities, and these broader
impacts have not been fully evaluated. Catastrophic
costs can be incurred by 32–83% of TB-affected
households related to TB care, and it is unknown if
families ever fully recover.7
The problems encountered after TB are not new,
but have yet to be addressed by national TB programs
or funding agencies. Only a small fraction of the
estimated US$6.8 billion expended by countries on
TB control, or the estimated US$ 772 million spent on
TB research has been directed to life and wellness
after ‘cure’.8 Here we present a summary of the
outcomes of the various workshops held at the
symposium (http://www.post-tuberculosis.com).
STRUCTURE AND AIMS
Conceptualised and implemented by an international
steering committee, the symposium had the five aims
presented in Table 1. The symposium was structured
as a working meeting with presentations and work-
shops covering a range of overlapping aspects of life
and illness after TB (Figure). The workshops provided
a forum for discussion of existing data and knowl-
edge gaps. The steering committee made use of the
Delphi Technique to reach consensus.9 In brief, the
Delphi Technique is a structured systematic commu-
nication method which relies on a panel of experts. It
uses a list of questions that is developed and refined in
Table 1 Aims of the 1st Post-Tuberculosis Symposium
Aim 1 To advocate for patients suffering with post-TB
complications
Aim 2 To facilitate face-to-face networking between leaders
in the field
Aim 3 To define the current state of knowledge surrounding
post-TB diseases
Aim 4 To discuss and achieve consensus on important aspects
of post-TB lung diseases
Aim 5 To produce a reference document for researchers and
workers in the field
TB¼ tuberculosis.
Figure Overview and relationship of the workshops held during the 1st Post-Tuberculosis Symposium. TB¼ tuberculosis.
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several rounds. The process is iterative, where
anonymously obtained information is recorded and
reported to delegates regularly. By ‘confronting’ the
delegates with each other’s ideas and insights in each
new round, consensus opinion is built. The process
was repeated until the threshold for agreement, set at
66%, was reached.
Consensus on terminology
A major barrier to progress in this emerging field has
been a lack of consensus in terminology and nomen-
clature.10 Priority was given to achieving consensus in
terminology, to effectively categorise and easily identify
relevant literature. Existing terminology used to
describe the long-term effects of TB following treat-
ment completion, were identified from the litera-
ture.4,10 Using three rounds of the Delphi process, all
delegates voted with a majority vote of 84% to
embrace the term ‘post-tuberculosis’. This term is
proposed as a prefix or adjective to describe residual
morbidity after TB and may be used within publica-
tions or as a key word for manuscript search terms.
Additionally, delegates within workshops reached
consensus on the specific terms of ‘lung disease/s’ to
describe the lung complications after TB (‘post-
tuberculosis lung disease/s (PTLD)’), and ‘economic,
social and psychological (ESP) well-being’ to describe
the psycho-social complications after TB (‘post-
tuberculosis economic, social and psychological
well-being’ (Post-TB ESP)’). This nomenclature will
be re-assessed and reviewed as new data emerge.
Epidemiology of post-tuberculosis lung disease
The aims of the workshop were to discuss 1) current
knowledge on disease burden due to PTLD, 2) relevant
PTLD-outcomes including how they are measured and
reported in epidemiological and clinical studies and 3)
current evidence on risk factors for PTLD.
The workshop participants agreed that whilst there
is strong evidence for the existence of PTLD,4,10,11
estimating its precise burden remains challenging.
Reasons for this include 1) diversity in clinical
phenotypes, 2) heterogeneity of outcome measures,
and 3) variable methodology for estimating the
fraction of post-TB lung abnormalities directly
attributable to TB and a lack of adequate control
for confounders. The risk factors for the development
of PTLD are also poorly established.
Apart from concrete PTLD case definitions, a
common methodological framework describing the
relevant diagnostic tools and interpretation strategies
for the measurement of PTLD and associated risk
factors was called for, with specific guidelines on the
interpretation and grading of results from each PTLD
assessment tool (see below). Where adapted guidelines
for PTLD are missing, existing guidelines and stan-
dardised testing instructions, including questionnaires,
showing the best fit to the studied population should be
chosen. Reports on PTLD-outcomes should include a
detailed description of the methodology used and
provide explanation on reasons for selection.
Additionally, potential research gaps related to
PTLD were identified and how to address these in
future clinical or epidemiological studies was dis-
cussed. There was agreement that next to proper case
definitions, the different phenotypes of PTLD should
be better characterised. Further follow up studies are
needed to define the clinical outcomes that are
meaningful for PTLD-related morbidity and mortal-
ity. Finally, the role of the long list of potential risk
factors, such as environmental, occupational, clinical
and behavioural exposures, affecting the develop-
ment of PTLD deserve further investigation.
Minimum case definition of post-tuberculosis lung
disease
Participants highlighted the need for a PTLD case
definition to be: broad and inclusive with sensitivity
prioritised over specificity; be suitable for use in low
and high resource settings; allow for dual-pathology
with both PTLD and other respiratory pathologies
occurring together; allow for patients to have both
PTLD from an old episode of TB disease and a
recurrent episode of active TB disease. It was acknowl-
edged that lung damage can be asymptomatic, but may
still be relevant to patient outcomes, and that
individuals who may have had a previously undocu-
mented or untreated episode of pulmonary TBmay still
have PTLD. Finally, it was noted that dual pathologies
are widely seen, and it can be challenging to identify the
primary contributor of a patient’s symptoms.
After three Delphi rounds, participants agreed on
the following minimum case definition:
Evidence of chronic respiratory abnormality, with or
without symptoms, attributable at least in part to
previous tuberculosis.
Measurement toolbox
There are multiple approaches to measuring PTLD,
and there was recognition that standardisation of
approaches and tools is preferable but is limited by
variable access to resources between settings, and
lack of prospective data to inform which ‘core’
aspects of disease or measurements best predict
long-term outcomes.
Delegates generated a list of potential approaches
(or a ‘toolbox’), from which professionals can choose
an approach to measure PTLD according to their
available resources (Table 2). Although it is not
possible to standardise measurement tools at present,
the need for standardisation and quality control was
highlighted. The importance of measuring co-expo-
sures or co-morbidities was discussed and a potential
list included.
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Severity scores
There was unanimous agreement that a validated
severity scoring system for PTLD, would be of great
value to identify patients at highest risk of adverse
outcome, for both clinical and research purposes.
Agreement was reached that a single, simple, easy to
use scoring tool should be developed for use in both
high- and low-resource settings, with flexibility accord-
ing to available tests. Potential outcome measures
against which this score could be derived included:
mortality; health related quality of life; rate of lung
function decline; rates of exacerbations/hospitalisa-
tions; as well as rates of TB recurrence. There was no
consensus around a single outcome to be prioritised,
and although mortality is likely the most important, all
were felt to be meaningful. The challenge of deriving
severity scores using a composite outcome, was
highlighted and more prospective data are required to
derive such scores.
Clinical patterns
The patterns of lung damage caused by TB are diverse
and vary both between and within individuals. A
‘core’ list of patterns of PTLD seen in clinical practice
was developed (Table 3). These patterns may occur
with or without symptoms, and that an individual
patient may have multiple patterns. Definitions were
not discussed in the workshop, but suggestions have
been provided for future review. It is anticipated that
the PTLD management strategies developed can be
targeted towards these core clinical patterns of
disease, and these will evolve over time.
Pathogenesis and prevention of damage
This workshop examined mechanisms and basic
science of TB disease, focusing on the interaction
between host, pathogen and environment in the
pathophysiology of tissue damage and the potential
for host-directed therapies (HDT) to prevent damage.
Key objectives were: 1) to identify pathophysiological
Table 2 Post-TB lung disease measurement toolbox, including aspects of disease and comorbidities/co-exposures which may be
measured in clinical and research practice, according to available resources
Category Parameter Measurement tool/item
Post-TB lung disease
measurement
Self-reported symptoms Shortness of breath (MRC/mMRC score), cough, sputum, wheeze, chest pain,
haemoptysis, fatigue
Clinical measures Observations: respiratory rate, oxygen saturation, heart rate, BMI
Investigations: arterial blood gas
Lung function Pre- and post-bronchodilator spirometry: FEV1, FVC, FEV25–75
Lung volumes: RV and TLC
Gas transfer
*Measurement, quality control and interpretation as per international norms strongly
recommended
Radiology CXR parameters
CT parameters
*No validated scoring tools as yet available
Functional capacity Submaximal tests: 6-minute walk (distance, nadir saturations, time to recovery), sit to
stand
Maximal tests: incremental shuttle, cardiopulmonary exercise testing
*Measurement, quality control and interpretation as per international norms strongly
recommended
Health-related quality
of life
Respiratory focused: St George’s Respiratory Questionnaire
General tools: Short-Form Health Survey (SF12/SF36), Karnofsky Performance Scale,
COPD Assessment Test
For economic analyses: WHO TB patient cost surveys
*Local translation, modification and validation strongly recommended
Disease behaviour Evidence of cor pulmonale: pedal oedema, echocardiography (pulmonary artery
pressures)
Evidence of exacerbations: exacerbation rate, hospitalisation rate
Microbiology: colonising/infecting organisms, including bacteria/mycobacteria/
viruses/fungi
Socio-economic
consequences
Mental health symptom screen (WHO self-reporting questionnaire-20 or Kessler
psychological distress scale); TB-related stigma (Stigma Scale for Chronic Illness or
Van Rie TB-related stigma tool); self-reported disability related to TB (Sheehan
Disability Scale)
Socio-economic information and patient costs (direct and indirect): WHO TB patient
cost surveys
Factors influencing
disease or outcomes
Co-exposures Respiratory exposures: smoking, substance abuse, biomass exposure, occupational
exposures
Environmental exposures: alcohol use, socio-economic situation
Comorbidities Preceding/concurrent respiratory disease: silicosis, COPD, other
Immunosuppression: HIV, diabetes mellitus, other
Other comorbidities: cardiovascular disease, other
TB¼ tuberculosis; MRC¼Medical Research Council; mMRC¼modified MRC; BMI¼body mass index; FEV1¼ forced expiratory volume in 1 sec; FVC¼ forced vital
capacity; RV¼residual volume; TLC¼ total lung capacity; CXR¼chest X-ray; CT¼computed tomography; COPD¼chronic obstructive pulmonary disease; WHO¼
World Health Organization; HIV¼ human immunodeficiency virus.
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pathways for investigation; 2) to review the current
landscape of HDT trials; 3) develop consensus on
appropriate endpoints for HDT trials; and 4) to
prioritise knowledge gaps, highlighting areas for
further research.
Talks highlighted evidence from cellular, ex-vivo,
animal and human observational studies indicating a
key role for host immune responses in pulmonary
tissue damage during active TB, including: host-
derived matrix metalloproteinase activity; neutrophil
fate (apoptosis, necrosis or netosis); the balance of
arachidonic acid derivatives in the release of pro- and
anti-inflammatory cytokines; macrophage fate (ne-
crosis) affecting M. tuberculosis survival and the
extent of the subsequent host inflammatory response
that ensues.12 There is a need to develop HDTwhich
interrupt specific pathways, focusing on preventing
and resolving cell death, matrix destruction and
fibrosis, which are considered the primary drivers of
morbidity. Two broad categories of HDT were
described: those that primarily reduce inflammation
or interrupt specific mechanisms for tissue damage,
and those that primarily induce antimicrobial activity
in phagocytic cells. A wide range of anti-inflamma-
tory candidates have been tested to date, including
corticosteroids, anti-TNF-alpha agents, phosphodi-
esterase inhibitors, anti-oxidants, and mTOR inhib-
itors. Ongoing or planned trials of antimicrobial
HDT include vitamin D, auranofin (an oral gold salt),
metformin (an AMPK activator), and imatinib (a
tyrosine kinase inhibitor).13 The majority of these
trials are designed to test drugs already licensed for
other indications.
During the workshop, priority was given to the most
suitable endpoint for HDT trials, as the majority of
trials have focused on time to culture conversion as the
sole primary endpoint. There was general agreement
that microbiological endpoints should no longer be the
sole primary endpoint of HDT trials. However, there
was no agreement on whether microbiological end-
points should be part of a co-primary endpoint. Those
in favour of including a microbiological endpoint
argued that it is important in establishing that there is
‘no harm’ by possible HDT; those opposed argued that
this outcome in itself should not dictate whether a
possible HDT is successful in improving lung damage
(e.g. inflammation) or other long-term outcomes.
Other endpoints discussed were similar to the toolkit
presented above (Table 2) but additionally included
PET/CT scanning; TB relapse and other biomarkers.
The following recommendations on clinical trial
design and candidate agents for evaluation were agreed
(Table 4): 1) There is a need to develop a pathway from
basic science to HDT clinical trials. 2) More clarity is
required on PTLD definitions, as discussed above, and
outcomes to inform HDT clinical study design. 3) It is
unlikely that there will be a ‘one size fits all’
preventative or HDTapproach. 4) HDTs may adverse-
ly affect microbiological outcomes (i.e. promote
discordant microbiological and lung health outcomes)
and thus may have the potential to worsen lung
damage. 5) All future HDT trials should include post-
TB endpoints. 6) HDT trials should include people
living with HIV infection.
Lung complications in children
Despite increasing awareness of PTLD in adults, there
are no data available in children. It is well docu-
mented that early life lung function ‘tracks’ through-
out life,14,15 pulmonary TB early in life could
therefore have long-lasting and devastating conse-
quences on lung health. A better understanding of the
impact of PTB on long-term respiratory morbidity in
children is urgently needed.
There are challenges to the diagnosis of PTLD in
children, including that TB diagnosis is made on
Table 3 Suggested PTLD clinical patterns with preliminary definitions (all categories are assumed to meet basic PTLD minimum case
definition)
Compartment Clinical patterns Suggested definition*
Airways TB-associated obstructive lung
disease
Airway obstruction (FEV1/FVC ratio , 0.7 OR , LLN) thought to be
primarily related to small airway disease
Bronchiectasis CT definition (evidence of airway dilatation) . diameter of adjacent vessel,
or non-tapering, OR CXR definition (evidence of ring and tramlines)
Parenchyma Cavitation A gas-filled space either within an area of pulmonary consolidation, or
surrounded by a thin wall
Parenchymal destruction Extensive destruction of lung tissue, with a gas-filled space occupying the
volume of 1 lobe
Fibrotic change Areas of parenchymal scarring, with associated volume loss
Aspergillus-related lung disease Evidence of aspergilloma on imaging OR chronic pulmonary aspergillosis
on imaging and blood testing
Pleural Chronic pleural disease Evidence of pleural thickening on CXR or CT imaging
Pulmonary vascular Pulmonary hypertension Elevated pulmonary artery pressures as estimated using doppler
echocardiography or measured at right heart catheterisation
Other Other Other pathology, not meeting the criteria above
* These definitions were not discussed at the Symposium, but are included as suggestions, and are expected to evolve as new data emerge.
PTLD¼ post-TB lung disease; TB¼ tuberculosis; FEV1¼ forced expiratory volume in 1 s; FVC¼ forced vital capacity; LLN¼ lower limit of normal; CT¼computed
tomography; CXR¼ chest X-ray.
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clinical grounds in the majority of children.16 There
was agreement that the ‘clinically diagnosed or
unconfirmed’ TB cases should be included when
investigating PTLD. In addition, the participants
identified the need to advocate for PTLD as a clinical
diagnosis in children with suspected TB and a history
of TB, while carefully excluding active TB disease.
The group proposed the following minimum case
definition for PTLD in children:
Evidence of chronic respiratory impairment in an
individual previously adequately treated for pulmo-
nary tuberculosis in whom active tuberculosis is
excluded, and in whom no other cause of chronic
lung disease is the predominant cause.
The case definition may require adaptation as more
evidence becomes available.
There is a lack of awareness and funding in this
field and long-term follow-up cannot be recommend-
ed as standard of care in routine services where the
healthcare system is already overburdened. Studies
are currently underway determining the long-term
burden of TB on lung health in children. This data is
required to obtain first estimates of the burden and
spectrum of PTLD in children, especially since we
expect PTLD to be heterogenous between the
different age groups.
Finally, the working group strongly recommended
that TB and its consequences should be viewed as a
life course disease and incidents that happen in early
childhood should be included and probed when
reviewing disease later in life.
Social, economic and psychological impact
There is little evidence available on social, economic
and psychological consequences of TB after treatment
completion.10 We do know that a substantial
proportion of TB survivors have chronic respiratory
disorders impairing quality of life (QoL), which are
likely to place a continued financial burden on them,
their families, their communities, and their health
systems.17 The global impact of TB-disease is most
likely underestimated because measures of disease
burden (such as disability-adjusted life year) do not
consider residual disability after treatment comple-
tion. The main aim of this workshop was to map
existing evidence, identify main research gaps and
generate research questions on the social, economic
and psychological impact of TB after cure.
Very little data and literature exists in this area, and
there is an urgent need to both quantify and qualify
TB patient experiences beyond TB cure. The highest
priority gaps identified (Table 4) were 1) at the
individual level: longitudinal data on clinical symp-
toms and lung impairment after TB together with
Table 4 Post-TB priority areas and research priorities
Topic Priority areas and research priorities
Epidemiology of PTLD Common methodological framework across studies
Follow-up studies defining meaningful clinical outcomes
Investigation of factors affecting development of PTLD (e.g., environmental, occupation,
clinical and behavioural factors)
Lung complications after TB Validation of tools used in PTLD
Evaluation of clinically meaningful phenotypes and predictors of morbidity and mortality
Development of validated severity scoring system
Pathogenesis and prevention Development of pathways from basic science to HDT trials
Assessment of most meaningful endpoints in HDT trials
Clinical trials of HDTs
Pulmonary consequences of TB in children Obtain disease estimates of burden of disease
Obtain estimates of spectrum of disease
Retrospective analysis of existing diagnostic, observational and treatment data
Social, economic and psychological impact For the individual: report disability (e.g., quality of health, mental health, pain, TB-related
stigma), economic consequences and proportion facing catastrophic total costs
For the community: quantify the economic and social impact of social and family
networks
For the health system: determine the cost of residual disability to the health system
Treatment and holistic management Optimal timing of assessment for post-TB complications
Non-pharmacological studies: pulmonary rehabilitation, education on self-management,
airway clearance techniques
Pharmacological studies: bronchodilators (e.g., long-acting beta-agonists, long-acting
anti-muscarinic agents)
Health care systems Prioritisation of advocacy for research funding to generate needed evidence
Development of guidelines for clinicians using available evidence and expert opinion
Engagement of international organisations, professional bodies and pharmaceutical
industries
Role of people affected by TB Peer group support and community interventions to reduce stigma
Sustainable funding for affected community-driven advocacy and support for their
involvement in research, policy and programmatic decisions
Former patient engagement to address recurrent TB
TB¼ tuberculosis; PTLD¼ post-TB lung disease; HDT¼ host-directed therapy.
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other indicators such as mental health, disability,
QoL, TB-related stigma etc.; 2) at the individual,
household and family level: data on the magnitude
and main drivers of different types of costs (direct and
indirect) incurred by TB patients and their households
after TB cure; economic impact of TB (e.g. work
productivity, proportion facing catastrophic total
costs etc.)8; social impact of TB and post-TB
morbidity on family and social networks; coping
strategies and resilience of TB survivors; 3) at the
health care system level: guidance to ensure contin-
uation and integration of health, social and psycho-
logical care; evidence on cost-effective interventions
to reduce post-TB disability; best practices on how to
provide health education and information about
‘after cure life’ during treatment. While tools are
available (Table 1) or can be adapted address these
research gaps, there is a need for robust epidemio-
logical studies and large multi-country cohort studies.
Treatment and holistic management
Only 56 studies addressing treatment and manage-
ment of PTLD have been published, with the majority
assessing lung surgery and ventilation techniques, and
almost no studies specific to PTLD.5 Only a few small
studies assessing pulmonary rehabilitation and med-
ication are available and were discussed. There was
agreement that existing TB treatment guidelines are
inadequate for the diagnosis, prevention and treat-
ment of PTLD, for which no guidelines exist.
Although specific guidelines are urgently needed, it
is challenging due to lack of evidence for treatment
specific to PTLD, and the diversity and spectrum of
PTLD outcomes. Additionally, there is no evidence to
either support or refute the use of the majority of
existing respiratory treatments used in other chronic
lung diseases (e.g. COPD, bronchiectasis etc.) being
extrapolated to PTLD patients.
There was consensus on the need for follow-up after
TB treatment as evidence emerges for increased
mortality, morbidity and recurrence risk in the post-
TB period.3–5,11,18 At a minimum, lung function
evaluation should be performed in order to detect and
better specify possible lung function impairment. This
assessment should help to identify patients suitable for
pulmonary rehabilitation. There is not yet universal
agreement on the setting (in- or outpatient) and
characteristics of pulmonary rehabilitation (e.g., psy-
chologicalsupport,education,exercise,pharmaceutical
treatment andoxygen) inpatientswithPTLD,however,
local and economical resources need to be taken into
consideration when developing guidelines.19–23
A list of health outcomes to measure success of
PTLD management strategies in clinical settings was
proposed similar to the ‘Post-TB toolbox’ (Table 2)
and included mortality. More research is urgently
needed on the effectiveness and comparative cost of
PTLD treatment options including: pulmonary reha-
bilitation; education about self-management; airway
clearance and bronchodilators.
Health care systems
This workshop discussed health systems as the
foundation for post-TB care and explored opportu-
nities to impact health systems through advocacy to
improve quality of care at every step in the TB care
cascade. The workshop drew from presentations on
health systems bottlenecks of care, personal testimo-
nies and experiences of survivors, a human centered
design approach where participants debated prioriti-
sation of barriers in the TB care cascade.
Two priority areas for advocacy were identified: 1)
evidence gaps in post-TB health and wellbeing; 2)
lack of clinical guidelines and algorithms for the
management of PTLD including the counselling of TB
patients. The workshop therefore recommended 1)
Prioritisation of advocacy for funding of research
needed to generate evidence. Such research must
address cost effectiveness of interventions and QoL;
2) Development of a guideline for clinicians, drawing
on the current evidence base and expert opinion
where necessary, and made available in collaboration
with The Union. This will be reviewed as more
evidence becomes available; 3) Development of
integrated counselling services for TB patients in
health systems.
The workshop recommended engagement of sev-
eral groups including international organisations,
professional bodies, pharmaceutical and other health-
care technology industries, TB affected communities
and former TB patients as advocacy partners.
The role of people affected by TB
The aim of this workshop was to reflect on the role of
former TB patients, their families and communities in
the context of the End TB Strategy and its first pillar:
‘Integrated, patient-centred tuberculosis care and
prevention’.24 Two central topics were addressed.
First, how to involve former patients in TB advocacy,
mentoring and support of new patients and commu-
nities. Second, to reduce the burden of recurrent TB,
we explored potential challenges to providing target-
ed health-care solutions to former patients.
Research has shown how former patients have
assisted in finding missing people with TB,25 increas-
ing the uptake of screening for latent infection26 and
preventive therapy among household contacts, and
improving treatment completion.27
There was also a discussion of the detrimental
effect of stigma in communities, its impact on
diagnostic delays and treatment non-completion.28
This emphasised the importance of clinic and
workplace sensitivity to unique patient experiences
as being central to prevent enacted stigma from health
workers and discriminatory practices from employ-
ers, both infringements on human rights. The
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importance of peer group support and interventions
improving community knowledge to reduce internal-
ised and anticipated stigma were emphasised.29
The group identified the need for sustainable
funding of advocacy work by former patients, to
ensure better access to new innovations, person-
centred research, and the community involvement in
policy and programmatic decisions.30 Former pa-
tients remain at high risk of TB even after completion
of adequate treatment5 and therefore require solu-
tions to prevent recurrence and reduce transmission
within communities.6,31 The group recommended
that former patients be engaged in the design of new
integrated solutions of post-treatment health-care
programs to address the prevention and management
of both recurrent TB and PTLD. Finally, patient
advocates called for the urgent development of
clinical guidelines for the management of patients
PTLD, which can be updated as evidence emerges.
CONCLUSION
Despite major global advances in the diagnosis and
treatment of TB, it is unlikely to be eradicated within
the next few decades, and the long-term complica-
tions are largely not addressed. This symposium was
an important step towards highlighting the physical,
psychological and socio-economic suffering that
continues long after treatment completion. The
difficulty in making definitive recommendations in
many domains was determined by the astounding
lack of data, emphasising the fact that this area has
largely been overlooked by TB programs, funders,
clinicians and researchers.
There is an urgent need for advocacy, increased
awareness, and funding of research to provide the
evidence base needed to develop robust guidelines.
Advocacy should be multi-disciplinary and involve
individuals affected by TB. Prevention of TB (and
therefore post-TB complications) should remain a
primary goal, but there may already be millions of
adults and children with post-TB sequelae for whom
prevention is too late. Urgent solutions are needed to
relieve suffering and prolong life amongst former
patients, and to mitigate the impact of post-TB
disability on the households and communities in
which they live. There is a need for guidelines to assist
health care providers managing these individuals in
the field, which will need to be frequently updated as
better evidence unfolds (Table 4).
Only by working together – and in strong
collaborative networks – will we be able to rapidly
address this previously unspoken epidemic emerging
from the shadows of TB.
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R E´ S U M E´
La TB, bien que curable, laisse fre´quemment les
individus avec un handicap chronique physique et
psychosocial, mais ces conse´quences ont a` ce jour e´te´
largement ne´glige´es. Le 1e symposium international post
TB a e´te´ entie`rement consacre´ au handicap apre`s la TB
et a couvert de nombreux sujets multidisciplinaires. Avec
la processus Delphi, un consensus a e´te´ atteint sur les
termes ‘‘post-TB’’, ‘‘maladie pulmonaire post-TB
(PTLD)’’, et ‘‘bien eˆtre e´conomique, social et
psychologique post TB’’, pour surmonter le de´fi
historique des variations de la terminologie dans la
litte´rature. Une de´finition de cas minimale a e´te´
propose´e par consensus pour la PTLD chez les adultes
et les enfants. Le manque de preuves suffisantes a entrave´
des recommandations de´finitives dans la majorite´ des
domaines, notamment dans la pre´vention et le
traitement de la PTLD, mais a mis en lumie`re le grand
besoin de recherche et des priorite´s ont e´te´ identifie´es.
L’he´te´roge´ne´ite´ de l’e´volution respiratoire et les
me´thodes de recherche pre´ce´demment utilise´es
compliquent l’estimation pre´cise du poids de la
maladie. Un consensus a cependant e´te´ atteint
proposant une boıˆte a` outils pour la mesure future de
la PTLD et sur les profils de PTLD a` envisager.
L’importance des conse´quences extra pulmonaires et
d’un handicap progressif tout au long de la vie a e´te´
identifie´e, dont la re´currence de la TB et l’augmentation
de la mortalite´. Les porte-parole des patients ont mis
l’accent sur le besoin d’aborder l’impact psychologique
et social post TB et appele´ a` une guidance clinique. Il y a
un besoin urgent de davantage de sensibilisation et de
recherche consacre´e aux complications post TB.
R E S UM E N
La TB es una enfermedad curable, pero con frecuencia
las personas conservan discapacidades cro´nicas fı´sicas y
psicosociales; hasta la fecha, no obstante, se ha prestado
poca atencio´n a estas consecuencias. El Primer Simposio
Internacional Postuberculosis se dedico´ exclusivamente
a las discapacidades posteriores a la TB y abordo´ una
diversidad de temas multidisciplinarios. Mediante el
me´todo Delphi se logro´ la unanimidad alrededor de los
te´rminos «postuberculosis», «enfermedad pulmonar
postuberculosis» (PTLD) y «bienestar econo´mico,
social y psicosocial postuberculosis», con el fin de
superar la dificultad histo´rica de una terminologı´a
variable en las publicaciones cientı´ficas. Se propuso
por consenso una definicio´n de caso mı´nima para la
PTLD en los adultos y los nin˜os. La falta de evidencia
suficiente obstaculizo´ la formulacio´n de
recomendaciones definitivas en la mayorı´a de las
esferas, incluida la prevencio´n y el tratamiento de la
PTLD, pero se puso de manifiesto la urgente necesidad
de nuevas investigaciones y se definieron las prioridades.
La heterogeneidad de los resultados respiratorios y los
me´todos de investigacio´n utilizados anteriormente
complico´ la estimacio´n exacta de la carga de la
enfermedad. Sin embargo, se pudo proponer de
manera una´nime un conjunto de herramientas para la
medicio´n de la PTLD en el futuro y los tipos de PTLD
que se tendrı´an en cuenta. Se establecio´ la importancia
de las consecuencias extrapulmonares y la discapacidad
progresiva a lo largo de la vida, incluida la recaı´da de la
TB y el aumento de la mortalidad. Los portavoces de los
pacientes destacaron la necesidad de abordar las
repercusiones psicolo´gicas y sociales postuberculosis y
solicitaron la elaboracio´n de directrices clı´nicas. Se
precisa con urgencia una mayor sensibilizacio´n a las
complicaciones posteriores a la TB y nuevas
investigaciones que estudien este problema.
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